Menu Search
Equities

COSCIENS Biopharma Inc

ET8:FRA

COSCIENS Biopharma Inc

Actions
  • Price (EUR)2.78
  • Today's Change-0.18 / -6.08%
  • Shares traded22.00
  • 1 Year change-48.06%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 14:56 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

  • Revenue in CAD (TTM)6.30m
  • Net income in CAD-17.57m
  • Incorporated1990
  • Employees21.00
  • Location
    COSCIENS Biopharma IncC/O Norton Rose Fulbright Canada Llp222 Bay Street, Suite 3000,PO Box 53TORONTO M5K 1E7CanadaCAN
  • Phone+1 (418) 652-8525
  • Fax+1 (418) 948-9191
  • Websitehttps://www.zentaris.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		CSCI:TOR since
announced		Transaction
value
Ceapro IncAnnounced14 Dec 202314 Dec 2023Announced58.62%15.86m
Data delayed at least 15 minutes, as of Nov 13 2024 17:05 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.